{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:03:23Z","timestamp":1758053003948,"version":"3.44.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"16-17","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005240","name":"Changjiang Scholar Program of Chinese Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005240","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.clinbiochem.2012.05.014","type":"journal-article","created":{"date-parts":[[2012,5,23]],"date-time":"2012-05-23T02:59:10Z","timestamp":1337741950000},"page":"1368-1373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Soluble C-X-C chemokine ligand 16 levels are increased in gout patients"],"prefix":"10.1016","volume":"45","author":[{"given":"Qi","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuebo","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaokun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuofeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0005","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/art.1780340716","article-title":"Monocyte-derived neutrophil chemotactic factor\/interleukin-8 is a potential mediator of crystal-induced inflammation","volume":"34","author":"Terkeltaub","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0010","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.4049\/jimmunol.0900525","article-title":"Overexpression of CXC chemokine ligand 14 exacerbates collagen-induced arthritis","volume":"184","author":"Chen","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0015","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1136\/ard.2006.066084","article-title":"Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis","volume":"66","author":"van Lieshout","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0020","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1002\/eji.200324136","article-title":"Microbial Toll-like receptor ligands differentially regulate CXCL10\/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN-gamma and provide a mechanism for enhanced synovial chemokine levels in septic arthritis","volume":"33","author":"Proost","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0025","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1172\/JCI117993","article-title":"Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis","volume":"95","author":"Kasama","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0030","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2249.1994.tb06109.x","article-title":"Expression of the chemokine superfamily in rheumatoid arthritis","volume":"97","author":"Hosaka","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0035","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/79738","article-title":"A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo","volume":"1","author":"Matloubian","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0040","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/art.21004","article-title":"Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints","volume":"52","author":"van d, V","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0045","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/art.21662","article-title":"CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway","volume":"54","author":"Ruth","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0050","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1189\/jlb.1204733","article-title":"Distribution and kinetics of SR-PSOX\/CXCL16 and CXCR6 expression on human dendritic cell subsets and CD4+ T cells","volume":"77","author":"Tabata","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0055","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1161\/01.ATV.0000124102.11472.36","article-title":"CXCL16\/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions","volume":"24","author":"Wuttge","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0060","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1074\/jbc.M311660200","article-title":"CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell\u2013cell adhesion and aortic smooth muscle cell proliferation","volume":"279","author":"Chandrasekar","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0065","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.2353\/ajpath.2009.080960","article-title":"CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein","volume":"174","author":"Gutwein","year":"2009","journal-title":"Am J Pathol"},{"issue":"11","key":"10.1016\/j.clinbiochem.2012.05.014_bb0070","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1002\/art.27650","article-title":"Pathogenic role of CXCR7 in rheumatoid arthritis","volume":"62","author":"Watanabe","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0075","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1002\/art.27518","article-title":"Expression and function of CXCL16 in a novel model of gout","volume":"62","author":"Ruth","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0080","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/ar2509","article-title":"Developments in the scientific and clinical understanding of gout","volume":"10","author":"So","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0085","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose\u2013response clinical trial examining safety and efficacy in patients with gout","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.clinbiochem.2012.05.014_bb0090","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/ard.2010.130476","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs","volume":"69","author":"Bertsias","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0095","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","article-title":"EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0100","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0105","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0110","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.clinbiochem.2012.05.014_bb0115","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.2353\/ajpath.2009.080960","article-title":"CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein","volume":"174","author":"Gutwein","year":"2009","journal-title":"Am J Pathol."},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0120","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2007.086611","article-title":"Regulation of CXCL16 expression and secretion by myeloid cells is not altered in rheumatoid arthritis","volume":"68","author":"van Lieshout","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0125","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1365-2362.2011.02473.x","article-title":"Increased plasma CXCL16 levels in patients with chronic kidney diseases","volume":"41","author":"Lin","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0130","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study","volume":"18","author":"Fliser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0135","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.clinbiochem.2012.05.014_bb0140","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1002\/art.21301","article-title":"Pathogenic role of the CXCL16\u2013CXCR6 pathway in rheumatoid arthritis","volume":"52","author":"Nanki","year":"2005","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912012002494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912012002494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:39:44Z","timestamp":1757864384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912012002494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":28,"journal-issue":{"issue":"16-17","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0009912012002494"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2012.05.014","relation":{},"ISSN":["0009-9120"],"issn-type":[{"type":"print","value":"0009-9120"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble C-X-C chemokine ligand 16 levels are increased in gout patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2012.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}